Bull
$40.32
Scenario price
$4.675
+0.015 (+0.32%)At close
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.
Sanuwave Health, Inc. (SNWV) is currently not a good buy due to its significant year-to-date decline of 83.82% and a low RSI of 34.916, indicating bearish momentum. While the company has shown some resilience with Q2 revenue exceeding revised guidance, the overall financial health remains concerning with a recent net income loss of $676,000 and a high debt-to-equity ratio of 688.05%.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

Sanuwave to Present Q2 2026 Financial Results on August 7

Sanuwave Health Q2 Revenue Update Shows Decline Yet Exceeds Guidance

Virax Biolabs Partners with Fosun Diagnostics, Shares Surge

Sanuwave (SNWV) Q4 2025 Earnings Transcript
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.
Sanuwave Health, Inc. (SNWV) is currently not a good buy due to its significant year-to-date decline of 83.82% and a low RSI of 34.916, indicating bearish momentum. While the company has shown some resilience with Q2 revenue exceeding revised guidance, the overall financial health remains concerning with a recent net income loss of $676,000 and a high debt-to-equity ratio of 688.05%.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.